ponatinib,blinatumomab
takeda,incyte,otsuka,amgen
['leusm', 'cml', 'ponatinib', 'blinatumomab', 'ph+ all']
#eha2023 | presents ph ii subgroup analysis results on efficacy &amp; safety of blinatumomab + ponatinib in pts with r/r ph+ all &amp; cml-lbp. cr/cri rates were 92% &amp; 86%, respectively. safety profile was favorable. no early deaths observed.
#allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm